This article was originally published by AJMC
Treatment Evolution in Multiple Myeloma
Looking at the current state of multiple myeloma management, experts discuss interest in novel therapies and MRD assessment to guide treatment.
Bruce Feinberg, DO: Hello, and welcome to this AJMC® webcast titled “Changing Patterns of Care in Multiple Myeloma.” I’m Dr Bruce Feinberg from Cardinal Health Specialty Solutions. Joining me today in this virtual discussion are my colleagues Dr Sagar Lonial of Winship Cancer Institute of Emory University, Stacey McCullough of Tennessee Oncology, and Ray Bailey of Florida Cancer Specialists.
Our panel of experts will review therapeutic options for multiple myeloma, understand challenges and best practices in dispensing multiple myeloma medications, and discuss the impact of COVID-19 [coronavirus disease 2019] on treatment patterns and dispensing.
The way we’re going to handle today’s discussion is in 4 segments. In the first, we’ll discuss the patient journey in multiple myeloma. In the second, therapeutic options for multiple myeloma patients. In the third, dispensing multiple myeloma oral medications. And in the fourth and final segment, we’ll discuss the impact of COVID-19 on treatment patterns and dispensing.
With that, let’s begin. I said we’re going to deal with the patient journey in this first segment. We’re very fortunate today because we have someone who has been following patients’ journeys for what could be 20-plus years. I’m being on the conservative side. I’ve known him. We’re both Atlanta based, so we’ve had a chance to work together in the past. It’s a remarkable opportunity to have Dr Sagar Lonial here with us to discuss this.
More importantly, very specific to this topic, is that incorporation of oral therapeutics for multiple myeloma was championed by him. He was 1 of the early adopters of RVd [lenalidomide, bortezomib, dexamethasone], which is 1 of the early triplet regimens and 1 that contains an oral drug.